SG10201710447QA - Pancreatic cancer biomarkers and uses thereof - Google Patents
Pancreatic cancer biomarkers and uses thereofInfo
- Publication number
- SG10201710447QA SG10201710447QA SG10201710447QA SG10201710447QA SG10201710447QA SG 10201710447Q A SG10201710447Q A SG 10201710447QA SG 10201710447Q A SG10201710447Q A SG 10201710447QA SG 10201710447Q A SG10201710447Q A SG 10201710447QA SG 10201710447Q A SG10201710447Q A SG 10201710447QA
- Authority
- SG
- Singapore
- Prior art keywords
- pancreatic cancer
- cancer biomarkers
- biomarkers
- pancreatic
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37368710P | 2010-08-13 | 2010-08-13 | |
US41868910P | 2010-12-01 | 2010-12-01 | |
US201161482480P | 2011-05-04 | 2011-05-04 | |
US201161482347P | 2011-05-04 | 2011-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201710447QA true SG10201710447QA (en) | 2018-02-27 |
Family
ID=45565264
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201710447QA SG10201710447QA (en) | 2010-08-13 | 2011-08-12 | Pancreatic cancer biomarkers and uses thereof |
SG2014007454A SG2014007454A (en) | 2010-08-13 | 2011-08-12 | Pancreatic cancer biomarkers and uses thereof |
SG2013002456A SG187045A1 (en) | 2010-08-13 | 2011-08-12 | Pancreatic cancer biomarkers and uses thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2014007454A SG2014007454A (en) | 2010-08-13 | 2011-08-12 | Pancreatic cancer biomarkers and uses thereof |
SG2013002456A SG187045A1 (en) | 2010-08-13 | 2011-08-12 | Pancreatic cancer biomarkers and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (3) | US20120040861A1 (en) |
EP (1) | EP2603622A4 (en) |
JP (1) | JP5931874B2 (en) |
KR (1) | KR101857462B1 (en) |
CN (2) | CN103415624B (en) |
AU (3) | AU2011289284B2 (en) |
BR (1) | BR112013003391B8 (en) |
CA (1) | CA2804857C (en) |
IL (1) | IL224014A (en) |
MX (2) | MX350533B (en) |
SG (3) | SG10201710447QA (en) |
WO (1) | WO2012021795A2 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10359425B2 (en) * | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
CN104777313B (en) | 2010-07-09 | 2017-09-26 | 私募蛋白质体公司 | Lung cancer biomarkers and application thereof |
WO2012021795A2 (en) | 2010-08-13 | 2012-02-16 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
NL2009015C2 (en) * | 2012-04-10 | 2013-10-15 | Biosparq B V | Method for classification of a sample on the basis of spectral data, method for creating a database and method for using this database, and corresponding computer program, data storage medium and system. |
CA2902841A1 (en) * | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
US20140272969A1 (en) * | 2013-03-14 | 2014-09-18 | Abbott Molecular Inc. | Cell preparations and cell supports and their use in theranosis |
CN103324846A (en) * | 2013-06-13 | 2013-09-25 | 浙江加州国际纳米技术研究院绍兴分院 | Screening method of colorectal cancer treatment prognosis biomarkers |
CN103310105A (en) * | 2013-06-13 | 2013-09-18 | 浙江加州国际纳米技术研究院绍兴分院 | Method for screening non-small-cell lung cancer curative effect biomarker |
CA2952390A1 (en) * | 2013-06-20 | 2014-12-24 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
KR101594981B1 (en) * | 2013-10-31 | 2016-02-17 | 에스케이텔레콤 주식회사 | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using the same |
KR101594980B1 (en) * | 2013-10-31 | 2016-02-17 | 에스케이텔레콤 주식회사 | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using the same |
US10330682B2 (en) | 2013-10-31 | 2019-06-25 | Sk Telecom Co., Ltd. | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using same |
KR20150129932A (en) * | 2014-05-12 | 2015-11-23 | 연세대학교 산학협력단 | A kit for pancreatic cancer diagnosis comprising complememt factor b-specific binding antibody |
US9506925B2 (en) | 2014-07-02 | 2016-11-29 | Dragon Victory Development Ltd. | Specific biomarker set for non-invasive diagnosis of liver cancer |
US9885718B2 (en) | 2014-07-02 | 2018-02-06 | Dragon Victory Development Ltd. | Specific biomarker set for non-invasive diagnosis of liver cancer |
WO2016060382A1 (en) * | 2014-10-17 | 2016-04-21 | 에스케이텔레콤 주식회사 | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer by using same |
KR20160045547A (en) | 2014-10-17 | 2016-04-27 | 에스케이텔레콤 주식회사 | Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using the same |
WO2016094330A2 (en) * | 2014-12-08 | 2016-06-16 | 20/20 Genesystems, Inc | Methods and machine learning systems for predicting the liklihood or risk of having cancer |
JP2016214239A (en) * | 2015-05-15 | 2016-12-22 | 国立大学法人高知大学 | Pancreatic cancer marker |
WO2017019588A1 (en) * | 2015-07-28 | 2017-02-02 | The Johns Hopkins University | Compositions and methods for detecting pancreatic cancer |
EP3347720A1 (en) * | 2015-09-09 | 2018-07-18 | Somalogic, Inc. | Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles |
EP3373820A4 (en) * | 2015-11-10 | 2019-06-26 | Exact Imaging Inc. | A system comprising indicator features in high-resolution micro-ultrasound images |
JP6498107B2 (en) * | 2015-11-30 | 2019-04-10 | 日本電信電話株式会社 | Classification apparatus, method, and program |
WO2017139254A1 (en) * | 2016-02-08 | 2017-08-17 | Somalogic, Inc. | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
GB201608192D0 (en) * | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
EP3458992B1 (en) * | 2016-05-19 | 2022-03-02 | Quartz Bio SA | Biomarkers signature discovery and selection |
JP7057913B2 (en) * | 2016-06-09 | 2022-04-21 | 株式会社島津製作所 | Big data analysis method and mass spectrometry system using the analysis method |
CN117058415A (en) * | 2016-10-28 | 2023-11-14 | 贝克曼库尔特有限公司 | Substance preparation evaluation system |
US11693007B2 (en) | 2017-02-24 | 2023-07-04 | Board Of Regents, The University Of Texas System | Assay for detection of early stage pancreatic cancer |
CN108931651A (en) * | 2017-05-24 | 2018-12-04 | 宜昌市中心人民医院 | A kind of kallikrein 7 detection method of content in blood and its as the application on the blood serum designated object of diagnosis of pancreatic cancer |
CN108931650A (en) * | 2017-05-24 | 2018-12-04 | 宜昌市中心人民医院 | A kind of kallikrein 7 activity test method in blood and its as the application on the blood serum designated object of diagnosis of pancreatic cancer |
US20200249235A1 (en) * | 2017-07-07 | 2020-08-06 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
CN107389776B (en) * | 2017-07-18 | 2020-06-02 | 宁波瑞瑧生物科技有限公司 | Analysis method for detecting drug distribution and application thereof |
US11062792B2 (en) * | 2017-07-18 | 2021-07-13 | Analytics For Life Inc. | Discovering genomes to use in machine learning techniques |
US11139048B2 (en) | 2017-07-18 | 2021-10-05 | Analytics For Life Inc. | Discovering novel features to use in machine learning techniques, such as machine learning techniques for diagnosing medical conditions |
KR101830314B1 (en) | 2017-07-26 | 2018-02-20 | 재단법인 구미전자정보기술원 | A method of providing information for the diagnosis of pancreatic cancer using bayesian network based on artificial intelligence, computer program, and computer-readable recording media using the same |
CN109425739B (en) * | 2017-08-31 | 2022-03-18 | 复旦大学 | Application of a group of proteins as tumor markers in preparation of malignant tumor diagnosis reagent and kit |
CA3095056A1 (en) * | 2018-04-13 | 2019-10-17 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
WO2019232361A1 (en) * | 2018-05-31 | 2019-12-05 | University Of Florida Research Foundation | Personalized treatment of pancreatic cancer |
US20210181188A1 (en) * | 2018-08-24 | 2021-06-17 | The Regents Of The University Of California | Mhc-ii genotype restricts the oncogenic mutational landscape |
US20200123616A1 (en) * | 2018-09-19 | 2020-04-23 | Bluestar Genomics, Inc. | Cell-free dna hydroxymethylation profiles in the evaluation of pancreatic lesions |
CN109919688B (en) * | 2019-03-29 | 2021-03-05 | 杭州电子科技大学 | Electronic cigarette product line planning method considering market factors |
CA3137738A1 (en) * | 2019-04-26 | 2020-10-29 | Sean Kelly | Device for personal predictive enrichment of a biomarker and methods of use thereof |
CN111584010B (en) * | 2020-04-01 | 2022-05-27 | 昆明理工大学 | Key protein identification method based on capsule neural network and ensemble learning |
WO2023282916A1 (en) | 2021-07-09 | 2023-01-12 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
IL301304A (en) * | 2020-09-10 | 2023-05-01 | Caris Mpi Inc | Metastasis predictor |
CN114250298A (en) * | 2020-09-23 | 2022-03-29 | 中国医学科学院北京协和医院 | DNA methylation marker of pancreatic ductal adenocarcinoma and application thereof |
KR20220091408A (en) * | 2020-12-22 | 2022-06-30 | 두에이아이(주) | Method for early diagnosis of pancreatic cancerusing artificial intelligence raman analysis technique |
EP4327098A1 (en) * | 2021-04-21 | 2024-02-28 | Reccan Diagnostics AB | Pancreatic cancer detection |
CN113096125A (en) * | 2021-05-11 | 2021-07-09 | 上海宝藤生物医药科技股份有限公司 | Method and device for determining concentration of low-density lipoprotein reagent and storage medium |
WO2023196571A1 (en) * | 2022-04-08 | 2023-10-12 | The Johns Hopkins University | Machine learning detection of hypermetabolic cancer based on nuclear magnetic resonance spectra |
WO2023239920A1 (en) * | 2022-06-10 | 2023-12-14 | City Of Hope | Biomarkers in pancreatic cancer |
KR102651556B1 (en) * | 2022-09-28 | 2024-03-27 | 주식회사 휴벳바이오 | Composition for Diagnosing Pancreatic Cancer for Use in CA19-9 Low Patient |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US20040254101A1 (en) * | 1995-06-06 | 2004-12-16 | Human Genome Sciences, Inc. | Colon specific gene and protein and cancer |
AU6688598A (en) | 1997-03-07 | 1998-09-22 | University Of Florida | Method for diagnosing and staging prostate cancer |
AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
US7090983B1 (en) | 1999-09-10 | 2006-08-15 | Takashi Muramatsu | Methods for detecting early cancer |
EP1472352A4 (en) | 2000-03-06 | 2005-10-12 | Smithkline Beecham Corp | Novel compounds |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6631330B1 (en) | 2000-08-21 | 2003-10-07 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers |
US6576423B2 (en) * | 2000-12-08 | 2003-06-10 | The Board Of Regents Of The University Of Nebraska | Specific mucin expression as a marker for pancreatic cancer |
EP1373896A2 (en) | 2001-03-12 | 2004-01-02 | MonoGen, Inc. | Cell-based detection and differentiation of disease states |
CA2444691A1 (en) | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
WO2003029273A2 (en) | 2001-09-28 | 2003-04-10 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
US20040241653A1 (en) | 2001-12-31 | 2004-12-02 | Elena Feinstein | Methods for identifying marker genes for cancer |
DK1918386T3 (en) | 2002-03-13 | 2012-01-02 | Genomic Health Inc | Gene expression profiles in tumor tissue biopsies |
US20050260639A1 (en) * | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
CN1703524B (en) * | 2002-09-30 | 2010-04-07 | 肿瘤疗法科学股份有限公司 | Genes and polypeptides relating to human pancreatic cancer |
EP1570080A4 (en) | 2002-11-15 | 2006-03-01 | Genomic Health Inc | Gene expression profiling of egfr positive cancer |
CN1726395A (en) * | 2002-12-17 | 2006-01-25 | 北京诺赛基因组研究中心有限公司 | Specific markers for pancreatic cancer |
AU2003294828A1 (en) * | 2002-12-17 | 2004-07-09 | Sinogenomax Co. Ltd. Chinese National Human Genomecenter | Specific markers for pancreatic cancer |
US8014952B2 (en) | 2002-12-18 | 2011-09-06 | Queen Elizabeth Hospital | Serum biomarkers in lung cancer |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
AU2003900747A0 (en) | 2003-02-18 | 2003-03-06 | Garvan Institute Of Medical Research | Diagnosis and treatment of pancreatic cancer |
CA2516553C (en) | 2003-02-20 | 2013-04-16 | Genomic Health, Inc. | Use of intronic rna to measure gene expression |
WO2004075713A2 (en) | 2003-02-26 | 2004-09-10 | Mount Sinai Hospital | Multiple marker assay for detection of ovarian cancer |
WO2004099432A2 (en) | 2003-05-02 | 2004-11-18 | The Johns Hopkins University | Identification of biomarkers for detecting pancreatic cancer |
US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CN1852974A (en) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | Compositions and methods for treating and diagnosing cancer |
DK1641810T4 (en) | 2003-06-24 | 2017-07-03 | Genomic Health Inc | Predicting the likelihood of cancer recurrence |
ES2905579T3 (en) | 2003-07-10 | 2022-04-11 | Genomic Health Inc | Expression profiling algorithm and test for prognosis of breast cancer relapse |
AU2004264948A1 (en) | 2003-08-15 | 2005-02-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Multifactorial assay for cancer detection |
US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
EP1682904A2 (en) | 2003-11-04 | 2006-07-26 | Roche Diagnostics GmbH | Method for distinguishing who classified aml subtypes |
US20050181451A1 (en) | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
EP2026071B1 (en) | 2004-02-19 | 2013-07-31 | Yale University | Identification of cancer protein biomarkers using proteomic techniques |
US8019552B2 (en) | 2004-03-05 | 2011-09-13 | The Netherlands Cancer Institute | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
ES2367311T3 (en) | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | MAP-2 PROTEOLYTIC DEGRADATION PRODUCTS AS DIAGNOSTIC BIOMARCATORS FOR NEURAL INJURIES. |
WO2005103281A2 (en) | 2004-04-26 | 2005-11-03 | Children's Medical Center Corporation | Platelet biomarkers for the detection of disease |
WO2006022643A1 (en) | 2004-07-26 | 2006-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting pancreatic disease |
WO2006022895A2 (en) | 2004-08-02 | 2006-03-02 | Children's Medical Center Corporation | Platelet biomarkers for cancer |
JP2006053113A (en) | 2004-08-16 | 2006-02-23 | Medical Proteoscope Co Ltd | Method and kit for diagnosing pulmonary adenocarcinoma lymph node metastasis |
JP4939425B2 (en) | 2004-11-05 | 2012-05-23 | ジェノミック ヘルス, インコーポレイテッド | Molecular indicators of prognosis and prediction of treatment response in breast cancer |
AU2005304824B2 (en) | 2004-11-05 | 2011-12-22 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
US8632983B2 (en) | 2005-04-15 | 2014-01-21 | Van Andel Research Institute | Biomarkers for pancreatic cancer and diagnostic methods |
US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
EP1904649A2 (en) | 2005-07-18 | 2008-04-02 | Epigenomics AG | Compositions and methods for cancer diagnostics comprising pan-cancer markers |
US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
EP2295571A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
US20080305962A1 (en) | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
US7582441B1 (en) | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
US8329408B2 (en) | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
JP2009516178A (en) | 2005-11-10 | 2009-04-16 | ユニバーシティー オブ ケンタッキー | Lung cancer diagnostic assay |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
US20070178504A1 (en) | 2005-12-22 | 2007-08-02 | Tracey Colpitts | Methods and marker combinations for screening for predisposition to lung cancer |
NZ593224A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (fap) for colorectal cancer prognosis |
AU2007211085A1 (en) | 2006-01-27 | 2007-08-09 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
CA2641315A1 (en) * | 2006-02-06 | 2007-08-16 | Tethys Bioscience, Inc. | Osteoporosis associated markers and methods of use thereof |
CA2645125A1 (en) * | 2006-03-02 | 2007-09-13 | Oncotherapy Science, Inc. | Methods for diagnosing pancreatic cancer using reg4 protein |
WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
US7888019B2 (en) | 2006-03-31 | 2011-02-15 | Genomic Health, Inc. | Genes involved estrogen metabolism |
US20100255518A1 (en) | 2006-04-04 | 2010-10-07 | Goix Philippe J | Highly sensitive system and methods for analysis of troponin |
WO2007146229A2 (en) | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
WO2008003024A2 (en) | 2006-06-28 | 2008-01-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Method and composition for diagnosing endometrial cancer |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
AU2007322206A1 (en) | 2006-11-13 | 2008-05-29 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring, and treatment of lung cancer |
WO2008086182A2 (en) | 2007-01-04 | 2008-07-17 | University Of Rochester | Use of gene signatures to design novel cancer treatment regimens |
US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
KR100846354B1 (en) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | Diagnostic biomarker for lung adenocarcinoma isolated from serum glycoproteins |
ES2442919T3 (en) * | 2007-03-27 | 2014-02-14 | Immunovia Ab | Signature / protein markers for the detection of adenocarcinoma |
US20080274481A1 (en) | 2007-03-28 | 2008-11-06 | Vermillion, Inc. | Methods for diagnosing ovarian cancer |
EP2515116A1 (en) | 2007-05-18 | 2012-10-24 | Duke University | Serum biomarkers for the early detection of lung cancer |
JP2010530217A (en) * | 2007-05-29 | 2010-09-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Molecules involved in the regulation of osteogenic and osteoclast activity and methods of use |
GB0717637D0 (en) | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
US8541183B2 (en) | 2007-09-11 | 2013-09-24 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof |
WO2009036123A1 (en) | 2007-09-11 | 2009-03-19 | Cancer Prevention And Cure, Ltd. | Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues |
US20100267041A1 (en) * | 2007-09-14 | 2010-10-21 | Predictive Biosciences, Inc. | Serial analysis of biomarkers for disease diagnosis |
AU2008302526A1 (en) | 2007-09-18 | 2009-03-26 | Board Of Regents Of The University Of Texas System | Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast |
EP2728017B1 (en) | 2007-11-19 | 2016-08-24 | Celera Corporation | Lung cancer markers and uses thereof |
EP2238455A4 (en) | 2008-01-18 | 2011-03-02 | Vatrix Medical Inc | Diagnostic biomarkers for vascular aneurysm |
GB0803192D0 (en) | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
US8067178B2 (en) | 2008-03-14 | 2011-11-29 | Genomic Health, Inc. | Gene expression markers for prediction of patient response to chemotherapy |
CN102057680A (en) * | 2008-07-04 | 2011-05-11 | 株式会社东芝 | Dynamic image encoding/decoding method and device |
US20120143805A1 (en) | 2008-09-09 | 2012-06-07 | Somalogic, Inc. | Cancer Biomarkers and Uses Thereof |
US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
MX2011002322A (en) | 2008-09-09 | 2011-05-10 | Somalogic Inc | Lung cancer biomarkers and uses thereof. |
US8580520B2 (en) * | 2008-09-15 | 2013-11-12 | Herlev Hospital | YKL-40 as a marker for gastrointestinal cancers |
US20120165217A1 (en) | 2008-10-06 | 2012-06-28 | Somalogic, Inc. | Cancer Biomarkers and Uses Thereof |
CA2737004A1 (en) | 2008-10-06 | 2010-04-15 | Somalogic, Inc. | Ovarian cancer biomarkers and uses thereof |
US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
WO2010049538A1 (en) | 2008-10-30 | 2010-05-06 | Centre de Recherche Public de la Santé | Biomarkers |
CA3153682A1 (en) | 2008-11-17 | 2010-05-20 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
EP2366162A1 (en) | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
US20110236903A1 (en) | 2008-12-04 | 2011-09-29 | Mcclelland Michael | Materials and methods for determining diagnosis and prognosis of prostate cancer |
AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
ES2623633T3 (en) | 2009-06-09 | 2017-07-11 | Gendiag.Exe, S.L. | Risk markers for cardiovascular disease |
AU2010260152A1 (en) | 2009-06-15 | 2012-02-02 | Cardiodx, Inc. | Determination of coronary artery disease risk. |
AU2010284199A1 (en) | 2009-08-19 | 2012-04-05 | The Cleveland Clinic Foundation | Marker detection for characterizing the risk of cardiovascular disease or complications thereof |
WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
EP2483697B2 (en) * | 2009-10-01 | 2017-07-05 | Phenomenome Discoveries Inc. | Method to diagnose pancreatic cancer |
US9683996B2 (en) | 2009-10-22 | 2017-06-20 | The Regents Of The University Of California | Assessment of solid tumor burden |
WO2011059721A1 (en) | 2009-10-29 | 2011-05-19 | Tethys Bioscience, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
CN102858999A (en) * | 2009-12-01 | 2013-01-02 | 简要生物科学有限公司 | Classification of cancers |
AU2010328019A1 (en) | 2009-12-09 | 2012-06-28 | Aviir, Inc. | Biomarker assay for diagnosis and classification of cardiovascular disease |
NZ705645A (en) | 2010-01-11 | 2016-05-27 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
US9404926B2 (en) | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
US9689039B2 (en) | 2010-02-10 | 2017-06-27 | The Regents Of The University Of California | Salivary biomarkers for lung cancer detection |
WO2011100472A1 (en) | 2010-02-10 | 2011-08-18 | The Regents Of The University Of California | Salivary transcriptomic and proteomic biomarkers for breast cancer detection |
EP2542696B1 (en) | 2010-03-01 | 2016-09-28 | Caris Life Sciences Switzerland Holdings GmbH | Biomarkers for theranostics |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
CN104777313B (en) | 2010-07-09 | 2017-09-26 | 私募蛋白质体公司 | Lung cancer biomarkers and application thereof |
WO2012021795A2 (en) | 2010-08-13 | 2012-02-16 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
CA2809282C (en) | 2010-09-27 | 2017-09-12 | Somalogic, Inc. | Mesothelioma biomarkers and uses thereof |
CN110444287B (en) | 2011-04-29 | 2024-02-06 | 癌症预防和治疗有限公司 | Methods for identifying and diagnosing pulmonary diseases using a classification system and kits therefor |
CA2843756A1 (en) | 2011-08-22 | 2013-02-28 | Somalogic, Inc. | Renal cell carcinoma biomarkers and uses thereof |
RU2651708C2 (en) | 2011-09-30 | 2018-04-23 | Сомалоджик, Инк. | Cardiovascular risk event prediction and uses thereof |
US9434779B2 (en) | 2012-03-19 | 2016-09-06 | The Brigham And Women's Hospital, Inc. | Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure |
EP3071588A4 (en) | 2013-11-21 | 2017-08-02 | Somalogic, Inc. | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto |
-
2011
- 2011-08-12 WO PCT/US2011/047570 patent/WO2012021795A2/en active Application Filing
- 2011-08-12 CA CA2804857A patent/CA2804857C/en active Active
- 2011-08-12 KR KR1020137003215A patent/KR101857462B1/en active IP Right Grant
- 2011-08-12 CN CN201180049408.2A patent/CN103415624B/en active Active
- 2011-08-12 CN CN201610479435.8A patent/CN106198980B/en active Active
- 2011-08-12 BR BR112013003391A patent/BR112013003391B8/en active IP Right Grant
- 2011-08-12 JP JP2013525961A patent/JP5931874B2/en active Active
- 2011-08-12 MX MX2016010635A patent/MX350533B/en unknown
- 2011-08-12 EP EP11817097.6A patent/EP2603622A4/en not_active Withdrawn
- 2011-08-12 SG SG10201710447QA patent/SG10201710447QA/en unknown
- 2011-08-12 SG SG2014007454A patent/SG2014007454A/en unknown
- 2011-08-12 AU AU2011289284A patent/AU2011289284B2/en active Active
- 2011-08-12 MX MX2013001042A patent/MX341517B/en active IP Right Grant
- 2011-08-12 SG SG2013002456A patent/SG187045A1/en unknown
- 2011-08-12 US US13/208,903 patent/US20120040861A1/en not_active Abandoned
-
2012
- 2012-12-30 IL IL224014A patent/IL224014A/en active IP Right Grant
-
2013
- 2013-09-06 US US14/020,334 patent/US20140073522A1/en not_active Abandoned
-
2015
- 2015-05-28 AU AU2015202907A patent/AU2015202907B2/en active Active
-
2016
- 2016-12-06 AU AU2016269430A patent/AU2016269430B2/en active Active
-
2017
- 2017-08-17 US US15/679,643 patent/US11041866B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201710447QA (en) | Pancreatic cancer biomarkers and uses thereof | |
HK1256822A1 (en) | Prostate cancer ncrna and uses thereof | |
IL223295A0 (en) | Lung cancer biomarkers and uses thereof | |
IL252163A0 (en) | Lung cancer biomarkers and uses thereof | |
EP2443259A4 (en) | Autism-associated biomarkers and uses thereof | |
EP2622104A4 (en) | Mesothelioma biomarkers and uses thereof | |
EP2536854A4 (en) | Personalized tumor biomarkers | |
EP2625292A4 (en) | Biomarkers of cancer | |
EP2382331A4 (en) | Cancer biomarkers | |
HK1206414A1 (en) | Biomarkers for gastric cancer and uses thereof | |
GB201016139D0 (en) | Cancer phosholipidome | |
EP2564200B8 (en) | Cancer biomarkers and methods of use thereof | |
EP2622091A4 (en) | Colon and pancreas cancer peptidomimetics | |
GB201021502D0 (en) | Biomarkers | |
EP2457092A4 (en) | Cancer biomarker and the use thereof | |
GB201008340D0 (en) | Biomarkers | |
EP2819749A4 (en) | Autism-associated biomarkers and uses thereof | |
GB201018056D0 (en) | Biomarkers | |
GB201211158D0 (en) | Biomarkers and uses thereof | |
GB201005561D0 (en) | Biomarkers | |
GB201001444D0 (en) | Biomarkers | |
GB201004442D0 (en) | Biomarker | |
EP2554994A4 (en) | Biomarkers | |
EP2501845A4 (en) | Biomarkers of cancer | |
GB201010316D0 (en) | Biomarkers |